Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isosorbide Dinitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.88 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | BCHE | P06276 | 6/20 | 0.63 |
| ▸ | GSR | P00390 | 8/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosorbide Dinitrate SCHEMBL918539 | 1.00 | ALDH1A1 (0.88) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL19528695 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL9439417 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL29532755 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL309369 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL8253 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL1553054 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL3008938 | 0.91 | ALDH1A1 (0.95) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL714959 | 0.91 | ALDH1A1 (0.95) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL919022 | 0.91 | MAPT (0.93) | ALDH1A1MAPTBCHEGSRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019191010-A1 | PERSONALIZED TREATMENT METHOD FOR CONGESTIVE HEART FAILURE | AARDVARK THERAPEUTICS INC. (US) | 2019-10-03 | — | — | WO | claimed |
| US-20060177504-A1 | Combination pain medication | SUNDHARADAS RENJIT | 2006-08-10 | — | — | US | claimed |
| US-11166931-B2 | Induction of arteriogenesis with an NO (nitric oxide) donor | G. POHL-BOSKAMP GMBH & CO. KG (DE) | 2021-11-09 | — | — | US | disclosed |
| WO-2019191010-A1 | PERSONALIZED TREATMENT METHOD FOR CONGESTIVE HEART FAILURE | AARDVARK THERAPEUTICS INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019191010-A1 | PERSONALIZED TREATMENT METHOD FOR CONGESTIVE HEART FAILURE | AARDVARK THERAPEUTICS INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| EP-2877170-B1 | INDUCTION OF ARTERIOGENESIS WITH NITROGLYCERINE | G POHL BOSKAMP GMBH & CO KG (DE) | 2019-04-10 | — | — | EP | disclosed |
| EP-3412285-A2 | INDUCTION OF ARTERIOGENESIS | G. Pohl-Boskamp GmbH & Co. KG (DE) | 2018-12-12 | — | — | EP | disclosed |
| US-20170172966-A1 | INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONOR | G. POHL-BOSKAMP GMBH & CO. KG (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20150164845-A1 | INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONOR | POHL BOSKAMP G GMBH & CO KG (DE) | 2015-06-18 | — | — | US | disclosed |
| EP-2877170-A1 | INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONOR | G. Pohl-Boskamp GmbH & Co. KG (DE) | 2015-06-03 | — | — | EP | disclosed |
| US-20150099270-A1 | METHOD OF SCREENING PHARMACEUTICALS FOR DRUG INTERACTIONS AND NEPHROTOXICITY | DOWLING THOMAS C (US) | 2015-04-09 | — | — | US | disclosed |
| EP-1212053-A1 | METHODS OF TREATING AND PREVENTING CONGESTIVE HEART FAILURE WITH HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | Nitromed, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017528-A1 | METHODS OF TREATING AND PREVENTING CONGESTIVE HEART FAILURE WITH HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | NITROMED, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| US-5952378-A | Methods and means for drug administration | PHARMACIA & UPJOHN AB (SE) | 1999-09-14 | — | — | US | disclosed |
| EP-0777483-A1 | METHODS AND MEANS FOR DRUG ADMINISTRATION | Pharmacia AB (SE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005840-A1 | METHODS AND MEANS FOR DRUG ADMINISTRATION | PHARMACIA AB (SE) | 1996-02-29 | — | — | WO | disclosed |
| US-5374430-A | Increased density of gastric controlled release unit by means of weighting agent to increase residence time in human stomach | LONDON SCHOOL OF PHARMACY (GB) | 1994-12-20 | — | — | US | disclosed |
| EP-0265061-B1 | PHARMACEUTICAL FORMULATION | London School of Pharmacy Innovations Ltd (GB) | 1992-01-08 | — | — | EP | disclosed |
| US-4938967-A | Pharmaceutical formulations | LONDON SCHOOL OF PHARMACY INNOVATIONS LTD. (GB) | 1990-07-03 | — | — | US | disclosed |
| EP-0265061-A1 | Pharmaceutical formulation | London School of Pharmacy Innovations Ltd (GB) | 1988-04-27 | — | — | EP | disclosed |